Teclistamab by Johnson & Johnson is a new hope for refractory or relapsing multiple myeloma.
Janssen
Posted inCOVID-19, Infections, Research
Three Billion Omicron Cases
Omicron, a new variant of the SARS-CoV-2 coronavirus, will infect nearly 40% of the world’s population.
Posted inAutoimmune Diseases, New Drugs, Rare/Orphan Diseases, Regulatory
Vyvgart: New Drug to Treat Myasthenia Gravis
Efgartigimod developed by Argenx is a strong competitor to Soliris.
Posted inCOVID-19, Infections, Research
Omicron Variant: Latest Scientific News, Findings, Evidence, and Developments
Up-to-date scientific information about the new Omicron variant of SARS-CoV-2/COVID-19.
Posted inAutoimmune Diseases, New Drugs, Regulatory
Zeposia: New Drug for Ulcerative Colitis
Oral ozanimod will provide clinical remission of ulcerative colitis for a third of patients.
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Ponvory: Another Drug for Multiple Sclerosis
Ponesimod is a new drug that changes the course of multiple sclerosis and is a direct competitor to Gilenya (fingolimod), Mayzent (siponimod), and Zeposia (ozanimod).
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Zeposia: New Drug to Treat Relapsing Multiple Sclerosis
Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.